Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calaspargase pegol-mknl + decitabine + venetoclax
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
calaspargase pegol-mknl + decitabine + venetoclax is an investigational combination therapy being evaluated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy). The regimen combines three distinct mechanisms: calaspargase pegol-mknl is a pegylated recombinant L-asparaginase that depletes the amino acid asparagine, which leukemic cells cannot synthesize; decitabine is a hypomethylating agent that inhibits DNA methyltransferase to reverse epigenetic silencing of tumor suppressor genes; and venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2. This triplet therapy is currently being studied in a Phase 2 clinical trial led by the M.D. Anderson Cancer Center, specifically targeting pediatric, adolescent, and young adult populations who have failed prior therapies.
- Other names
- calaspargase pegol-mknl, decitabine, and venetoclax combination
02
Targets
BCL-2 (BCL-2 family)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on calaspargase pegol-mknl + decitabine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calaspargase pegol-mknl + decitabine + venetoclax.